Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn's disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Decreased number of colonic tuft cells in quiescent ulcerative colitis patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Challenges and obstacles in the transition process through the eyes of the gastroenterologist

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

OBJECTIVE: Two meta-analyses have found that the risk of relapse in Crohn's disease (CD) was ~40 and 50% 1 and 2 years, respectively, after withdrawal of anti-tumour necrosis factor-α (anti-TNFα). The aim of this study was to evaluate relapse rates in CD when thiopurine therapy was optimized before anti-TNFα withdrawal.

PATIENTS AND METHODS: An observational study was conducted including patients with CD in remission with optimized thiopurine therapy before anti-TNFα withdrawal. We defined optimized thiopurine therapy as 6-thioguanine levels of at least 150 nmol/mmol haemoglobin (∼300 pmol×10 red blood cells) and clinical/biochemical remission as Harvey-Bradshaw Index of 5 or less and faecal calprotectin of 200 µg/g or less.

RESULTS: We included 33 patients (median age: 31 years, 55% males, and median disease duration: 7 years) followed for a median of 36 months. A total of three (9%) patients relapsed during the first year and six patients (in total 27%) relapsed after 2 years. After 2 years, none of the additional patients relapsed. The disease duration and duration of anti-TNFα treatment and faecal calprotectin levels before inclusion did not predict relapse. Calprotectin levels of at least 180 after 1 year predicted relapse at year 2.

CONCLUSION: This study found that 73% of patients with CD maintained remission (>2 years) when thiopurine therapy was optimized before withdrawal of anti-TNFα. Additional prospective evidence is needed to confirm the findings.

OriginalsprogEngelsk
TidsskriftEuropean journal of gastroenterology & hepatology
Vol/bind30
Udgave nummer10
Sider (fra-til)1155-1158
ISSN0954-691X
DOI
StatusUdgivet - 1 sep. 2018

ID: 54888794